(NASDAQ: MCRB) Seres Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Seres Therapeutics's earnings in 2025 is $136,000.On average, 4 Wall Street analysts forecast MCRB's earnings for 2025 to be -$74,102,473, with the lowest MCRB earnings forecast at -$99,384,493, and the highest MCRB earnings forecast at -$10,461,526. On average, 3 Wall Street analysts forecast MCRB's earnings for 2026 to be -$72,649,193, with the lowest MCRB earnings forecast at -$109,846,019, and the highest MCRB earnings forecast at -$20,923,051.
In 2027, MCRB is forecast to generate -$12,205,113 in earnings, with the lowest earnings forecast at -$12,205,113 and the highest earnings forecast at -$12,205,113.